Louis Frederic Diehl, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 2400 Pratt St Suite 5000, DUMC Box 3961, Durham, NC 27710
Phone (919) 668-1000
Email address louis.diehl@duke.edu

Research interests include Hodgkin disease, non-Hodgkin lymphomas, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia.

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Walter Reed Army Medical Center, 1978 - 1981
  • Medical Resident, Medicine, Walter Reed Army Medical Center, 1975 - 1978
  • M.D., Georgetown University, 1975

Publications

Boyle, John, Anne W. Beaven, Louis F. Diehl, Leonard R. Prosnitz, and Chris R. Kelsey. “Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy..” Oncology (Williston Park) 28, no. 12 (December 2014): 1074–84.

PMID
25510806
Scholars@Duke

Hutchings, Martin, Lale Kostakoglu, Jan Maciej Zaucha, Bogdan Malkowski, Alberto Biggi, Iwona Danielewicz, Annika Loft, et al. “In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma..” J Clin Oncol 32, no. 25 (September 1, 2014): 2705–11. https://doi.org/10.1200/JCO.2013.53.2838.

PMID
25071108
Full Text

Brander, Danielle, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro, Joseph O. Moore, and Anne Beaven. “Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma..” Leuk Lymphoma 54, no. 12 (December 2013): 2627–30. https://doi.org/10.3109/10428194.2013.784969.

PMID
23488610
Full Text

Held, Lauren A., David Rizzieri, Gwynn D. Long, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Mitchell E. Horwitz, Nelson J. Chao, and Cristina Gasparetto. “A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma..” Cancer Invest 31, no. 3 (March 2013): 172–76. https://doi.org/10.3109/07357907.2012.756109.

PMID
23406188
Full Text

Morris, Tod A., Carlos M. DeCastro, Louis F. Diehl, Jon P. Gockerman, Anand S. Lagoo, Zhiguo Li, Joseph O. Moore, David A. Rizzieri, and Arati V. Rao. “Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia..” Leuk Res 37, no. 1 (January 2013): 28–31. https://doi.org/10.1016/j.leukres.2012.09.016.

PMID
23046833
Full Text

DiLillo, D. J., J. B. Weinberg, A. Yoshizaki, M. Horikawa, J. M. Bryant, Y. Iwata, T. Matsushita, et al. “Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function..” Leukemia 27, no. 1 (January 2013): 170–82. https://doi.org/10.1038/leu.2012.165.

PMID
22713648
Full Text

Kelsey, Chris R., Anne W. Beaven, Louis F. Diehl, and Leonard R. Prosnitz. “Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks..” Oncology (Williston Park) 26, no. 12 (December 2012): 1182–93.

PMID
23413599
Scholars@Duke

Rao, Arati, David A. Rizzieri, Eduardo Vanegas, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Donna Adams, Julie Warzecho, and Carlos Decastro. “Pilot Study of Sorafenib for Myelodysplastic Syndrome.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.

Scholars@Duke

Rao, Arati, Ghazi Khan, David A. Rizzieri, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Anne W. Beaven, Donna Adams, Julie Warzecho, and Carlos Decastro. “Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS.” In Blood, Vol. 120. AMER SOC HEMATOLOGY, 2012.

Scholars@Duke

Pages